查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612742

癌症生物標記市場：按生物標記類型、癌症類型、技術、應用、最終用戶 - 2025-2030 年全球預測

Cancer Biomarkers Market by Biomarker Type (Genetic, Protein), Cancer Type (Blood Cancer, Breast Cancer, Colorectal Cancer), Technology, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癌症生物標記市場價值為283.1億美元，預計到2024年將達到312.3億美元，複合年成長率為10.71%，預計到2030年將達到577.5億美元。

癌症生物標記是存在於血液、其他體液和組織中的生物分子，顯示癌症的存在。其範圍包括檢測、診斷、預後和治療監測，這在個人化醫療中非常重要。癌症生物標記研究對於早期檢測、更準確的診斷和改善患者預後的客製化治療至關重要。生物標記廣泛應用於臨床診斷、藥物發現研發、癌症研究、放射學、病理學等。最終用途多種多樣，包括醫院、實驗室、診斷中心、生技和製藥公司。關鍵的成長要素包括癌症發病率上升、癌症基因組研究資金增加、體學技術進步以及對非侵入性檢測程序的需求不斷增加。潛在的機會在於蛋白質體學、基因組學和生物資訊學的進步，這些進步有可能發現新穎的生物標記物，以及醫療基礎設施正在迅速改善的新興市場。然而，他們面臨著諸如生物標記發現和檢驗的高成本、監管複雜性以及影響結果解釋的生物標記表達的可變性等挑戰。為了克服這些問題，重要的是利用巨量資料分析和人工智慧來提高預測準確性並整合多組體學資料以發現更準確的標記。最佳創新領域包括開發液態切片技術、利用微型RNA和胞外體探索生物標記以及提高就地檢驗能力。學術機構、醫療保健提供者和生技公司之間的合作可以加速創新並將新的解決方案推向市場。癌症生物標記市場是一個高度動態和競爭的市場，其特點是技術快速發展和不斷創新，以滿足癌症早期檢測和個人化治療的迫切需求。採用次世代定序（NGS）技術並探索資料分析中的人工智慧等綜合方法可以提供競爭優勢。

主要市場統計
基準年[2023] 283.1億美元
預計年份 [2024] 312.3億美元
預測年份 [2030] 577.5億美元
複合年成長率（%） 10.71%

市場動態：揭示快速發展的癌症生物標記市場的關鍵市場洞察

供需的動態交互作用正在改變癌症生物標記市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 人群中癌症盛行率增加
    • 增加早期癌症檢測的強度和宣傳宣傳活動
    • 醫療基礎設施和醫療支出的增加
  • 市場限制因素
    • 與研發相關的高成本
  • 市場機會
    • 用於檢測侵襲性肝癌的優質生物標記的出現
    • 積極的研究活動旨在引入新的生物標記以早期檢測肺癌
  • 市場挑戰
    • 複雜而嚴格的規定

波特的五力：駕馭癌症生物標記市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解癌症生物標記市場的外部影響

外部宏觀環境因素在塑造癌症生物標記市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解癌症生物標記市場的競爭格局

癌症生物標記市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣癌症生物標記市場供應商的績效評估

FPNV定位矩陣是評估癌症生物標記市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製癌症生物標記市場的成功之路

癌症生物標記市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人群中癌症盛行率增加
      • 增加早期癌症檢測的強度和宣傳宣傳活動
      • 擴大醫療基礎設施和醫療支出
    • 抑制因素
      • 研發成本高
    • 機會
      • 用於檢測惡性肝癌的更好生物標記的出現
      • 積極的研究活動旨在引入新的生物標記以早期檢測肺癌
    • 任務
      • 複雜且嚴格的監管合規
  • 市場區隔分析
    • 生物標記的類型：蛋白質生物標記效用透過血液和組織中所含的蛋白質檢測癌症的存在
    • 應用：診斷中優先選擇生物標記以進行早期檢測，以改善患者的治療結果
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按生物標記類型分類的癌症生物標記市場

  • 遺傳的
  • 蛋白質

第 7 章按癌症類型分類的癌症生物標記市場

  • 血癌
  • 乳癌
  • 大腸直腸癌
  • 肺癌
  • 卵巢癌
  • 攝護腺癌
  • 皮膚癌
  • 胃癌

第8章癌症生物標記市場：依技術分類

  • 生物資訊學
  • 細胞遺傳學
  • 成像技術
  • 免疫檢測
  • 體學技術

第9章癌症生物標記市場：依應用分類

  • 診斷
  • 藥物發現與開發
  • 預言
  • 風險評估

第 10 章癌症生物標記市場：按最終用戶分類

  • 學術/癌症研究中心
  • 醫院
  • 專業中心

第11章美洲癌症生物標記市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區癌症生物標記市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的癌症生物標記市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Chromacord 與喬治亞醫學院結成策略聯盟，加強 NSCLC 診斷能力
    • 晶泰科技與CK Life Sciences加強人工智慧合作，打造下一代癌症診斷
    • 提高癌症治療的準確性：FDA啟動試驗計畫來規範腫瘤藥物的伴同性診斷測試
  • 戰略分析和建議

公司名單

  • Abbott Laboratories Inc.
  • Agilent Technologies, Inc.
  • ASURAGEN, INC.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • Bruker Corporation
  • Charles River Laboratories International, Inc.
  • Enzo Biochem, Inc.
  • Epigenomics AG
  • Eurofins Scientific SE
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Merck KGaA
  • Myriad Genetics, Inc.
  • PerkinElmer, Inc.
  • Pfizer Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Siemens Healthcare GmbH
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-437517DB6E4D

The Cancer Biomarkers Market was valued at USD 28.31 billion in 2023, expected to reach USD 31.23 billion in 2024, and is projected to grow at a CAGR of 10.71%, to USD 57.75 billion by 2030.

Cancer biomarkers are biological molecules found in blood, other body fluids, or tissues, indicating the presence of cancer. Their scope includes detection, diagnosis, prognosis, and therapeutic monitoring, making them critical in personalized medicine. Cancer biomarker research is essential for early detection, more accurate diagnoses, and tailored treatments that improve patient outcomes. They are extensively applied in clinical diagnostics, drug discovery, and development as well as cancer research, radiology, and pathology. The end-use scope spans hospitals, research laboratories, diagnostic centers, and biotechnology and pharmaceutical companies. Key growth factors include the rising prevalence of cancer, increased funding for cancer genomics research, technological advancements in omics technologies, and growing demand for non-invasive testing procedures. Potential opportunities lie in advancements in proteomics, genomics, and bioinformatics, which may uncover novel biomarkers, and in emerging markets where healthcare infrastructure is rapidly improving. However, the market faces challenges such as high costs of biomarker discovery and validation, regulatory complexities, and variability in biomarker expression that can impact the interpretation of results. To overcome these, leveraging big data analytics and artificial intelligence to enhance predictive accuracy and integrating multi-omics data to discover more precise markers are crucial. Best areas for innovation include developing liquid biopsy technologies, exploring microRNA and exosome-based biomarkers, and improving point-of-care testing capabilities. Collaborations between academic institutions, healthcare providers, and biotech firms can accelerate innovation and bring new solutions to market. The cancer biomarker market is highly dynamic and competitive, characterized by rapid technological evolution and a constant drive for innovation to meet the pressing demands of early cancer detection and personalized treatment. Adoption of next-generation sequencing (NGS) technologies and the exploration of integrative approaches like artificial intelligence in data analysis could offer a competitive edge.

KEY MARKET STATISTICS
Base Year [2023] USD 28.31 billion
Estimated Year [2024] USD 31.23 billion
Forecast Year [2030] USD 57.75 billion
CAGR (%) 10.71%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Biomarkers Market

The Cancer Biomarkers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer disorders among population
    • Rising initiatives and awareness campaigns for early cancer detection
    • Growing healthcare infrastructure and healthcare spending
  • Market Restraints
    • High costs associated with research and development
  • Market Opportunities
    • Emergence of better biomarkers for detection of aggressive liver cancer
    • Robust research activities to introduce new biomarkers for early detection of lung cancer
  • Market Challenges
    • Complex and stringent regulatory compliances

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Biomarkers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Biomarkers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Biomarkers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Biomarkers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Biomarkers Market

A detailed market share analysis in the Cancer Biomarkers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Biomarkers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Biomarkers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Biomarkers Market

A strategic analysis of the Cancer Biomarkers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc., Agilent Technologies, Inc., ASURAGEN, INC., Bio-Rad Laboratories, Inc., bioMerieux SA, Bristol-Myers Squibb Company, Bruker Corporation, Charles River Laboratories International, Inc., Enzo Biochem, Inc., Epigenomics AG, Eurofins Scientific SE, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies Inc., Hologic, Inc., Illumina, Inc., Merck KGaA, Myriad Genetics, Inc., PerkinElmer, Inc., Pfizer Inc., QIAGEN N.V, Quest Diagnostics Incorporated, Siemens Healthcare GmbH, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Biomarker Type, market is studied across Genetic and Protein.
  • Based on Cancer Type, market is studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Skin Cancer, and Stomach Cancer.
  • Based on Technology, market is studied across Bioinformatics, Cytogenetics, Imaging Technology, Immunoassays, and OMICS Technology.
  • Based on Application, market is studied across Diagnostics, Drug Discovery & Development, Prognostics, and Risk Assessment.
  • Based on End User, market is studied across Academic & Cancer Research Centers, Hospitals, and Speciality Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer disorders among population
      • 5.1.1.2. Rising initiatives and awareness campaigns for early cancer detection
      • 5.1.1.3. Growing healthcare infrastructure and healthcare spending
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with research and development
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of better biomarkers for detection of aggressive liver cancer
      • 5.1.3.2. Robust research activities to introduce new biomarkers for early detection of lung cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Complex and stringent regulatory compliances
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Biomarker Type: Usability of protein biomarkers in detecting the presence of cancer through proteins found in blood or tissue
    • 5.2.2. Application: Preferences for biomarkers in diagnostic for early-stage detection to improve treatment outcomes for patients
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Biomarkers Market, by Biomarker Type

  • 6.1. Introduction
  • 6.2. Genetic
  • 6.3. Protein

7. Cancer Biomarkers Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Blood Cancer
  • 7.3. Breast Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Lung Cancer
  • 7.6. Ovarian Cancer
  • 7.7. Prostate Cancer
  • 7.8. Skin Cancer
  • 7.9. Stomach Cancer

8. Cancer Biomarkers Market, by Technology

  • 8.1. Introduction
  • 8.2. Bioinformatics
  • 8.3. Cytogenetics
  • 8.4. Imaging Technology
  • 8.5. Immunoassays
  • 8.6. OMICS Technology

9. Cancer Biomarkers Market, by Application

  • 9.1. Introduction
  • 9.2. Diagnostics
  • 9.3. Drug Discovery & Development
  • 9.4. Prognostics
  • 9.5. Risk Assessment

10. Cancer Biomarkers Market, by End User

  • 10.1. Introduction
  • 10.2. Academic & Cancer Research Centers
  • 10.3. Hospitals
  • 10.4. Speciality Centers

11. Americas Cancer Biomarkers Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cancer Biomarkers Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cancer Biomarkers Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Strategic Collaboration between ChromaCode and Medical College of Georgia to Enhance NSCLC Diagnostic Capabilities
    • 14.3.2. Enhanced AI Collaboration Between XtalPi and CK Life Sciences for Next-Generation Cancer Diagnostics
    • 14.3.3. Enhancing Precision in Cancer Treatment: FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories Inc.
  • 2. Agilent Technologies, Inc.
  • 3. ASURAGEN, INC.
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux SA
  • 6. Bristol-Myers Squibb Company
  • 7. Bruker Corporation
  • 8. Charles River Laboratories International, Inc.
  • 9. Enzo Biochem, Inc.
  • 10. Epigenomics AG
  • 11. Eurofins Scientific SE
  • 12. Exact Sciences Corporation
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. GE HealthCare Technologies Inc.
  • 15. Hologic, Inc.
  • 16. Illumina, Inc.
  • 17. Merck KGaA
  • 18. Myriad Genetics, Inc.
  • 19. PerkinElmer, Inc.
  • 20. Pfizer Inc.
  • 21. QIAGEN N.V
  • 22. Quest Diagnostics Incorporated
  • 23. Siemens Healthcare GmbH
  • 24. Sysmex Corporation
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. CANCER BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER BIOMARKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. CANCER BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. CANCER BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER BIOMARKERS MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROTEIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OMICS TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ACADEMIC & CANCER RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SPECIALITY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. THAILAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. DENMARK CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. EGYPT CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. FINLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. FRANCE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. GERMANY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. ITALY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. NORWAY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. POLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. QATAR CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SPAIN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. TURKEY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. CANCER BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 244. CANCER BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023